Future directions in SMA treatment involve incorporating SMN-independent therapies alongside SMN-dependent ones to provide broader benefits, especially for patients diagnosed later or with milder forms of SMA. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.